Ruxolitinib versus standard therapy for the treatment of polycythemia vera
- PMID: 25629741
- PMCID: PMC4358820
- DOI: 10.1056/NEJMoa1409002
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Abstract
Background: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea.
Methods: We randomly assigned phlebotomy-dependent patients with splenomegaly, in a 1:1 ratio, to receive ruxolitinib (110 patients) or standard therapy (112 patients). The primary end point was both hematocrit control through week 32 and at least a 35% reduction in spleen volume at week 32, as assessed by means of imaging.
Results: The primary end point was achieved in 21% of the patients in the ruxolitinib group versus 1% of those in the standard-therapy group (P<0.001). Hematocrit control was achieved in 60% of patients receiving ruxolitinib and 20% of those receiving standard therapy; 38% and 1% of patients in the two groups, respectively, had at least a 35% reduction in spleen volume. A complete hematologic remission was achieved in 24% of patients in the ruxolitinib group and 9% of those in the standard-therapy group (P=0.003); 49% versus 5% had at least a 50% reduction in the total symptom score at week 32. In the ruxolitinib group, grade 3 or 4 anemia occurred in 2% of patients, and grade 3 or 4 thrombocytopenia occurred in 5%; the corresponding percentages in the standard-therapy group were 0% and 4%. Herpes zoster infection was reported in 6% of patients in the ruxolitinib group and 0% of those in the standard-therapy group (grade 1 or 2 in all cases). Thromboembolic events occurred in one patient receiving ruxolitinib and in six patients receiving standard therapy.
Conclusions: In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera. (Funded by Incyte and others; RESPONSE ClinicalTrials.gov number, NCT01243944.).
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4358820/bin/nihms665386f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4358820/bin/nihms665386f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4358820/bin/nihms665386f3.gif)
Comment in
-
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.N Engl J Med. 2015 Apr 23;372(17):1670-1. doi: 10.1056/NEJMc1502524. N Engl J Med. 2015. PMID: 25901432 No abstract available.
-
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.N Engl J Med. 2015 Apr 23;372(17):1670. doi: 10.1056/NEJMc1502524. N Engl J Med. 2015. PMID: 25901433 No abstract available.
Similar articles
-
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2. Ann Hematol. 2018. PMID: 29396713 Clinical Trial.
-
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21. Haematologica. 2016. PMID: 27102499 Free PMC article. Clinical Trial.
-
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. Lancet Haematol. 2020. PMID: 31982039 Free PMC article. Clinical Trial.
-
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26. Cancer Chemother Pharmacol. 2016. PMID: 27017614 Free PMC article. Review.
-
Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?Future Oncol. 2016 Mar;12(6):739-49. doi: 10.2217/fon-2015-0023. Epub 2016 Feb 5. Future Oncol. 2016. PMID: 26846873 Review.
Cited by
-
Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study.BMC Cancer. 2024 Apr 26;24(1):531. doi: 10.1186/s12885-024-12301-x. BMC Cancer. 2024. PMID: 38671390 Free PMC article.
-
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05735-7. Online ahead of print. Ann Hematol. 2024. PMID: 38662203
-
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.Target Oncol. 2024 May;19(3):343-357. doi: 10.1007/s11523-024-01049-w. Epub 2024 Apr 20. Target Oncol. 2024. PMID: 38643346 Clinical Trial.
-
Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century.Ann Hematol. 2024 Apr 9. doi: 10.1007/s00277-024-05723-x. Online ahead of print. Ann Hematol. 2024. PMID: 38592500 Review.
-
Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.J Clin Med. 2024 Mar 9;13(6):1574. doi: 10.3390/jcm13061574. J Clin Med. 2024. PMID: 38541800 Free PMC article. Review.
References
-
- Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272–4290. - PubMed
-
- Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:507–516. - PubMed
-
- Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician. 2004;69:2139–2144. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials